EcoDrugPlus

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPVAG00000005823
Gene Symbol: RAF1
1 Cross references
215 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSPVAG00000008233
Gene Symbol: ROCK1
1 Cross references
215 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSPVAG00000008634
Gene Symbol: ROCK2
1 Cross references
304 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSPVAG00000017785
Gene Symbol: SRC
1 Cross references
262 Possible Orthologues:

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSPVAG00000014863
Gene Symbol: TEK
1 Cross references
164 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSPVAG00000001459
Gene Symbol: TTK
1 Cross references
203 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSPVAG00000000294
Gene Symbol: UGCG
1 Cross references
211 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSPVAG00000013037
Gene Symbol: WEE1
1 Cross references
226 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSPVAG00000000705
Gene Symbol: YES1
1 Cross references
269 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSPVAG00000000840
Gene Symbol: ACHE
1 Cross references
233 Possible Orthologues:

Activin A Receptor Like Type 1

Ensembl ID : ENSPVAG00000004951
Gene Symbol: ACVRL1
1 Cross references
353 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSPVAG00000012774
Gene Symbol: ACVR2B
1 Cross references
257 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).